Cargando…
Persistent Immune Activation in CVID and the Role of IVIg in Its Suppression
Common variable immunodeficiency (CVID) is one of the most common and clinically important primary immune deficiencies. CVID patients have poor humoral immunity, resulting in recurrent infections of the gastrointestinal and upper respiratory tracts, as well as increased incidence of some forms of ca...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4267274/ https://www.ncbi.nlm.nih.gov/pubmed/25566250 http://dx.doi.org/10.3389/fimmu.2014.00637 |
_version_ | 1782349133291454464 |
---|---|
author | Paquin-Proulx, Dominic Sandberg, Johan K. |
author_facet | Paquin-Proulx, Dominic Sandberg, Johan K. |
author_sort | Paquin-Proulx, Dominic |
collection | PubMed |
description | Common variable immunodeficiency (CVID) is one of the most common and clinically important primary immune deficiencies. CVID patients have poor humoral immunity, resulting in recurrent infections of the gastrointestinal and upper respiratory tracts, as well as increased incidence of some forms of cancers and autoimmune diseases. The treatment for CVID is IgG replacement, often given as intravenous immunoglobulins (IVIg). IVIg consists of monomeric IgG purified from pooled plasma from healthy donors and is used to treat an increasing number of conditions including autoimmune diseases. In the case of CVID, IVIg has mainly been seen as reconstitution therapy, providing patients with pathogen-specific antibodies. Recent evidence shows that IVIg has diverse effects on the immune system of CVID patients, and one important component is that IVIg alleviates the state of chronic immune activation. In this review, we will discuss causes and consequences of persistent immune activation in CVID, possible underlying mechanisms for how IVIg treatment reduces immune activation, and implications for our understanding of primary as well as acquired immune deficiencies. |
format | Online Article Text |
id | pubmed-4267274 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-42672742015-01-06 Persistent Immune Activation in CVID and the Role of IVIg in Its Suppression Paquin-Proulx, Dominic Sandberg, Johan K. Front Immunol Immunology Common variable immunodeficiency (CVID) is one of the most common and clinically important primary immune deficiencies. CVID patients have poor humoral immunity, resulting in recurrent infections of the gastrointestinal and upper respiratory tracts, as well as increased incidence of some forms of cancers and autoimmune diseases. The treatment for CVID is IgG replacement, often given as intravenous immunoglobulins (IVIg). IVIg consists of monomeric IgG purified from pooled plasma from healthy donors and is used to treat an increasing number of conditions including autoimmune diseases. In the case of CVID, IVIg has mainly been seen as reconstitution therapy, providing patients with pathogen-specific antibodies. Recent evidence shows that IVIg has diverse effects on the immune system of CVID patients, and one important component is that IVIg alleviates the state of chronic immune activation. In this review, we will discuss causes and consequences of persistent immune activation in CVID, possible underlying mechanisms for how IVIg treatment reduces immune activation, and implications for our understanding of primary as well as acquired immune deficiencies. Frontiers Media S.A. 2014-12-16 /pmc/articles/PMC4267274/ /pubmed/25566250 http://dx.doi.org/10.3389/fimmu.2014.00637 Text en Copyright © 2014 Paquin-Proulx and Sandberg. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Paquin-Proulx, Dominic Sandberg, Johan K. Persistent Immune Activation in CVID and the Role of IVIg in Its Suppression |
title | Persistent Immune Activation in CVID and the Role of IVIg in Its Suppression |
title_full | Persistent Immune Activation in CVID and the Role of IVIg in Its Suppression |
title_fullStr | Persistent Immune Activation in CVID and the Role of IVIg in Its Suppression |
title_full_unstemmed | Persistent Immune Activation in CVID and the Role of IVIg in Its Suppression |
title_short | Persistent Immune Activation in CVID and the Role of IVIg in Its Suppression |
title_sort | persistent immune activation in cvid and the role of ivig in its suppression |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4267274/ https://www.ncbi.nlm.nih.gov/pubmed/25566250 http://dx.doi.org/10.3389/fimmu.2014.00637 |
work_keys_str_mv | AT paquinproulxdominic persistentimmuneactivationincvidandtheroleofiviginitssuppression AT sandbergjohank persistentimmuneactivationincvidandtheroleofiviginitssuppression |